


Analysis of Carbidopa and Levodopa

(Under the Condition of draft for USP, Carbidopa, Levodopa, and Entacapone Tablets ,
Assay, Procedure 1: CARBIDOPA AND LEVODOPA)



Standard solution

Conditions

System : Chromaster PLUS (HITACHI)
Column : InertSustainSwift C18 (GL Sciences Inc.)
 (5 μ m, 250 x 4.6 mm I.D.)
Column Cat. No. : 5020-88027
Eluent : A) $\text{CH}_3\text{CN}/\text{CH}_3\text{OH}=50/50$, v/v
 B) Buffer*

Time (min)	A (vol %)	B (vol %)
0.0	3	97
12.0	3	97
26.0	70	30
29.0	70	30
31.0	3	97
38.0	3	97

Flow Rate : 1.0 mL/min
Col. Temp. : 30 $^{\circ}\text{C}$
Detection : UV 280 nm (Chromaster 5430 DAD)
Injection Vol. : 10 μL
Sample : Standard in 0.1N HCl

Analyte:

1. Levodopa 0.16 mg/mL
 2. Carbidopa 0.04 mg/mL

Relative retention times

Levodopa : 0.4
 Carbidopa : 1.0

Tailing factor

the peak of 1 : $(0.8 \leq) 1.29 (\leq 1.8)$
 the peak of 2 : $(0.8 \leq) 1.15 (\leq 1.8)$

RSD of

the peak area of 1 (%)(n=6) : 0.30 (≤ 1.0)
 the peak area of 2 (%)(n=6) : 0.32 (≤ 1.0)

* : Dissolve 1.8 g of sodium phosphate, monobasic, anhydrous in 900 mL of water. Add 2 mL of phosphoric acid, and dilute with water to 1000 mL.